BeiGene
BGNE
#984
Rank
ยฃ15.70 B
Marketcap
ยฃ140.80
Share price
1.55%
Change (1 day)
-2.21%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total assets

Total assets on the balance sheet as of September 2024 : ยฃ4.58 Billion

According to BeiGene 's latest financial reports the company's total assets are ยฃ4.58 Billion. A companyโ€™s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.

BeiGene - Total assets on balance sheet (from 2014 to 2024)

Total assets by year

Year Total assets Change
2023-12-31ยฃ4.55 B-13.58%
2022-12-31ยฃ5.27 B-16.61%
2021-12-31ยฃ6.32 B53.89%
2020-12-31ยฃ4.10 B234.19%
2019-12-31ยฃ1.22 B-30.63%
2018-12-31ยฃ1.77 B128.89%
2017-12-31ยฃ0.77 B135.43%
2016-12-31ยฃ0.32 B317.41%
2015-12-31ยฃ78.79 M128.78%
2014-12-31ยฃ34.44 M381.53%
2013-12-31ยฃ7.15 M

Total Assets for similar companies or competitors

Company Total assets differencediff. Country
ยฃ14.28 M-99.69%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ1.77 B-61.31%๐Ÿ‡บ๐Ÿ‡ธ USA